Directed evolution of a regioselective halogenase for increased thermostability

US10344267B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10344267-B2
Application numberUS-201415100065-A
CountryUS
Kind codeB2
Filing dateNov 26, 2014
Priority dateNov 27, 2013
Publication dateJul 9, 2019
Grant dateJul 9, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds and methods are providing involving RebH variants with improved properties. directed evolution based on random mutagenesis was employed to generate a series of RebH variants. RebH variants with improved thermostability and increased activity at elevated temperatures were generated.

First claim

Opening claim text (preview).

The invention claimed is: 1. An isolated RebH variant polypeptide of SEQ ID NO: 1 comprising at least one amino acid substitution, wherein the at least one amino acid substitution results in improved halogenating activity; and wherein the at least one amino acid substitution is selected from the group consisting of S2P, I52T, A58V, M71V, M71T, M71A, M71C, N75K, E96V, D101G, S110P, S110L, F111S, G112S, G112D, L113D, L113N, L114P, S130L, K145M, K145R, N166S, F171I, K187R, D203A, D203G, T213A, V225I, K237E, V256I, T258A, D264G, T283A, L289P, F312L, T322I, T348A, L380F, T394M, F396Y, F396L, R400C, T413A, E423D, A442V, S448P, L453P, F458S, F458L, E461G, F465C, F465L, N467T, N470S, A476T, A476V, V481A, Q494R, T496R, T496A, G504S, and R509Q, wherein the RebH variant polypeptide is at least 85% identical to SEQ ID NO:1. 2. The RebH variant of claim 1 comprising the amino acid substitutions S2P, M71V, K145M, N467T, N470S, and G112S. 3. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates an aromatic substrate. 4. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates a substrate regioselectively. 5. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays improved thermostability over wild-type RebH. 6. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays increased halogenating activity at an elevated temperature. 7. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates the wild-type RebH native substrate tryptophan. 8. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates non-native substrates. 9. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates a substrate and wherein the substrate comprises a molecule selected from the group consisting of indole, tryptoline, 2-methyltryptamine, eleagnine, pinoline, tetrahydroharmine, debromodesformylflustrabromine, yohimbine, evodiamine, pindolol, carazolol, and carvedilol. 10. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates using a halogen selected from the group consisting of fluoride, chloride, bromide and iodide. 11. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays a prolonged catalyst lifetime. 12. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays an increased tolerance to proteolysis. 13. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays an increased tolerance to organic solvents. 14. The RebH variant polypeptide of claim 1 , wherein the RebH variant polypeptide halogenates in the absence of a harsh chemical oxidant. 15. A RebH variant polypeptide comprising at least one amino acid substitution at position 2, 52, 58, 71, 75, 96, 101, 110, 111, 112, 113, 114, 130, 145, 166, 171, 187, 203, 213, 225, 237, 256, 258, 264, 283, 289, 312, 322, 348, 380, 394, 396, 400, 413, 423, 448, 453, 455, 458, 461, 465, 467, 470, 476, 481, 494, 496, 504 and/or 509 in SEQ ID NO:1, wherein the RebH variant polypeptide is at least 85% identical to SEQ ID NO:1. 16. The isolated RebH variant polypeptide of claim 1 , wherein the variant comprises at least a S2P substitution.

Assignees

Inventors

Classifications

  • aromatic (naphthacene C12P29/00) · CPC title

  • 4-Hydroxyphenylacetate 3-monooxygenase (1.14.14.9) · CPC title

  • Tryptophan 7-halogenase (1.14.14.7) · CPC title

  • Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system (alloxazine or isoalloxazine, e.g. riboflavine C12P25/00) · CPC title

  • Nitrogen as only ring hetero atom · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10344267B2 cover?
Compounds and methods are providing involving RebH variants with improved properties. directed evolution based on random mutagenesis was employed to generate a series of RebH variants. RebH variants with improved thermostability and increased activity at elevated temperatures were generated.
Who is the assignee on this patent?
Univ Chicago
What technology area does this patent fall under?
Primary CPC classification C12N9/0071. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).